Cyclerion Therapeutics, Inc. (CYCN)
| Market Cap | 15.73M+34.1% |
| Revenue (ttm) | n/a-12.6% |
| Net Income | n/a-244.7% |
| EPS | n/a-129.3% |
| Shares Out | 668.76K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 435,847 |
| Open | 3.72 |
| Previous Close | 23.52 |
| Day's Range | 2.82 - 23.52 |
| 52-Week Range | 2.82 - 59.36 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CYCN
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
$CYCN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CYCN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CYCN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CYCN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CYCN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CYCN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CYCN
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $113.77K |
| ONEQFidelity Nasdaq Composite Index ETF | $96.74K |
Estimated from each fund’s disclosed top holdings × AUM
CYCN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CYCN’s recent data — informational, not investment advice